The role of monoclonal antibodies in the treatment of lymphomas

Hsu, Jack W.; Dang, Nam H.

doi:10.1517/14712598.2012.755172

Cited by 4 publications

(4 citation statements)

References 94 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Monoclonal Abs have truly transfigured the way lymphoma is treated. Therapeutic Abs bind to and can kill tumor cells through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis . The key factors for the success of Ab-based therapy are the identification of valid target antigens and the development of effective Abs against these targets.…”

Section: Therapeutic Abs For Lymphoma Treatmentmentioning

confidence: 99%

“…pendent cellular cytotoxicity, and induction of apoptosis. 7 The key factors for the success of Ab-based therapy are the identification of valid target antigens and the development of effective Abs against these targets. Suitable antigens need to be highly expressed on the surface of tumor cells of interest but minimally expressed on normal tissues.…”

Section: ■ Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immuno-PET Imaging and Radioimmunotherapy of Lymphomas

2022

View full text Add to dashboard Cite

Monoclonal antibodies (Ab) have revolutionized the management of lymphomas, the most common hematologic malignancy in adults. Indeed, incorporation of rituximab into the regimen for indolent non-Hodgkin’s lymphomas (NHLs) has dramatically improved treatment response and disease outcome. Yet, newer Ab therapeutics against promising antigen targets need to be developed to treat refractory or relapsed patients. Treatment efficacy can be further enhanced by conjugating toxic molecules to the Abs. Radioimmunotherapy (RIT) harnesses Abs as vehicles for targeted delivery of therapeutic radionuclide payloads for direct killing of targeted tumor cells. Positron emission tomography (PET) with radiolabeled Abs (called immuno-PET) can facilitate the development of new Ab therapeutics and RIT by providing pharmacokinetic and pharmacodynamic information and by quantifying tumor antigen level relevant for treatment decision. Immuno-PET has recently gravitated toward labeling Abs with 89Zr, a radiometal with a 3.3 day half-life that is trapped following Ab internalization and thus provides high-resolution PET images with excellent contrast. Immuno-PET methods against major lymphoma antigens including CD20 and other promising targets are currently under development. With continued improvements, immuno-PET has the potential to be used in lymphoma management as an imaging biomarker for patient selection and assessment of treatment response.

show abstract

Section: Therapeutic Abs For Lymphoma Treatmentmentioning

confidence: 99%

Section: ■ Introductionmentioning

confidence: 99%

Immuno-PET Imaging and Radioimmunotherapy of Lymphomas

2022

View full text Add to dashboard Cite

show abstract

“…Combination of RTX with chemotherapy (e.g. RTX + CHOP) has improved treatment outcomes and is now considered the standard of care for many forms of NHL, including diffuse large B-cell lymphoma (DLBCL) [1]. However, resistance to RTX does occur and compromises the outcome of B-lineage NHL patients receiving RTX as part of their treatment plan [2].…”

Section: Targeting Cd20mentioning

confidence: 99%

“…A series of novel mAbs with specificity for a variety of surface antigens are currently under evaluation. These include anti-CD20 mAb (ofatumumab, veltuzumab, ocrelizumab, ocaratuzumab, obinutuzumab, ublituximab), anti-CD19 mAb (MOR208), anti-CD22 mAbs (epratuzumab, inotuzumab ozogamicin) and anti-CD16/CD30 mAb (TandAb ® AFM13) [1][2][3][4][5][6][7][8][9][10][11][12].…”

mentioning

confidence: 99%

Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non-Hodgkin’s Lymphoma (NHL)

Uçkun

2013

Transl Med

View full text Add to dashboard Cite

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Hansson

Gimsing

Badros

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients.Experimental Design: BI-505 was given intravenously, every 2 weeks, at escalating doses from 0.0004 to 20 mg/kg, with extension of therapy until disease progression for responding or stable patients receiving 0.09 mg/kg or higher doses.Results: A total of 35 patients were enrolled. The most common adverse events were fatigue, pyrexia, headache, and nausea. Adverse events were generally mild to moderate, and those attributed to study medication were mostly limited to the first dose and manageable with premedication and slower infusion. No maximum tolerated dose was identified. BI-505 0 s half-life increased with dose while clearance decreased, suggesting target-mediated clearance. The ICAM-1 epitopes on patient bone marrow myeloma were completely saturated at 10 mg/kg doses. Using the International Myeloma Working Group criteria, 7 patients on extended therapy had stable disease for more than 2 months.Conclusions: BI-505 can be safely administered at doses that saturate myeloma cell ICAM-1 receptors in patients. This study was registered at www.clinicaltrials.gov (NCT01025206).

show abstract

The role of monoclonal antibodies in the treatment of lymphomas

Cited by 4 publications

References 94 publications

Immuno-PET Imaging and Radioimmunotherapy of Lymphomas

Immuno-PET Imaging and Radioimmunotherapy of Lymphomas

Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non-Hodgkin’s Lymphoma (NHL)

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Contact Info

Product

Resources

About